Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Capital Expenditures (2022 - 2025)

Stoke Therapeutics has reported Capital Expenditures over the past 4 years, most recently at $578000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $578000.0 for Q4 2025, up 1056.0% from a year ago — trailing twelve months through Dec 2025 was $670000.0 (up 998.36% YoY), and the annual figure for FY2025 was $670000.0, up 998.36%.
  • Capital Expenditures for Q4 2025 was $578000.0 at Stoke Therapeutics, up from $41000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for STOK hit a ceiling of $2.8 million in Q3 2022 and a floor of -$47000.0 in Q3 2024.
  • Median Capital Expenditures over the past 4 years was $197000.0 (2023), compared with a mean of $394312.5.
  • Biggest five-year swings in Capital Expenditures: crashed 112.27% in 2024 and later surged 1056.0% in 2025.
  • Stoke Therapeutics' Capital Expenditures stood at $409000.0 in 2022, then crashed by 44.01% to $229000.0 in 2023, then plummeted by 78.17% to $50000.0 in 2024, then surged by 1056.0% to $578000.0 in 2025.
  • The last three reported values for Capital Expenditures were $578000.0 (Q4 2025), $41000.0 (Q3 2025), and $24000.0 (Q2 2025) per Business Quant data.